Harrison covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Regeneron, and Alnylam Pharma. According to TipRanks, Harrison has an average return of 7.6% and a 52.94% success rate on recommended stocks.
In addition to Morgan Stanley, Kodiak Sciences also received a Hold from Goldman Sachs’s Andrea Tan in a report issued on August 9. However, on August 10, Chardan Capital maintained a Buy rating on Kodiak Sciences (NASDAQ: KOD).
The company has a one-year high of $131.97 and a one-year low of $4.90. Currently, Kodiak Sciences has an average volume of 1M.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KOD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Read More on KOD:
- Nocera, Inc. Announces Closing of $6.58 Million Underwritten Public Offering
- Analysts Offer Insights on Healthcare Companies: Azenta (AZTA), AKOUOS (AKUS) and Viridian Therapeutics (VRDN)
- AMD Stock: Well-Positioned to Continue Taking Market Share
- Clene (CLNN) Gets a Buy from H.C. Wainwright
- Stock Market Today – Monday, Aug 15: What You Need to Know